Investors
News
Subscribe
About Us
Corporate Overview
Corporate Presentation
Management Team
Board of Directors
Lead Scientific Team
Company History
Intellectual Property
Astaxanthin
Overview
History and Background
Benefits of Use
Manufacturing
Scientific Literature
Commercialization
Strategy
Addressable Markets
Other Programs
Newsroom
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact Us
Investor Relations
Press Releases
Investors
Overview
News / Events
Press Releases
Media Coverage
IR Calendar
Presentations
Email Alerts
Company Info
Profile
Management Team
Contacts
FAQ
Financial Info
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Tear Sheet
Contacts
RSS News Feed
All News
2019
2018
2017
2016
2015
2014
2013
2012
2011
2009
2007
2006
Cardax to Lead Plenary Session at Regenerative Medicine Conference
Nov 6, 2017
Cardax and GNC Sign Mutual Exclusivity Agreement for ZanthoSyn®
Oct 20, 2017
Cardax Welcomes Cardiovascular Research Breakthrough
Sep 19, 2017
Cardax Promotes David M. Watumull to COO; Partially Restores Compensation Company-Wide
Sep 7, 2017
Cardax Attracts $2.75M in Investment
Aug 28, 2017
Cardax Reports Q2 2017 Results
Aug 11, 2017
ZanthoSyn Going National with GNC
Aug 10, 2017
ZanthoSyn Now Available on GNC.com
Jun 27, 2017
Cardax Astaxanthin Compound Chosen for Important NIH Anti-Aging Research Program
Jun 18, 2017
Cardax Q1 2017 Revenues Triple vs. Prior Two Quarters Combined
May 15, 2017
1
2
3
4
5
6
7
News / Events
Press Releases
Media Coverage
IR Calendar
Presentations
Email Alerts
About Us
Corporate Overview
Corporate Presentation
Management Team
Board of Directors
Lead Scientific Team
Company History
Intellectual Property
Astaxanthin
Overview
History and Background
Benefits of Use
Manufacturing
Scientific Literature
Commercialization
Strategy
Addressable Markets
Other Programs
Newsroom
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact Us
